Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.
Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
